Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.…
Tvardi Therapeutics Advances Next-Generation Oral STAT3 Inhibitor TTI-109 Toward IND in Inflammatory Bowel Disease Following FDA Pre-IND Feedback
Tvardi Therapeutics (NASDAQ: TVRD) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 12 employees.
The shares were at 0.9893 USD on 20 November 2026, down 74.9% over 52 weeks. Its 52-week range is 0.7751 USD to 5.050 USD: the price is 80.4% below the high and 27.6% above the low.
Its market capitalisation is 13.22M USD.
Tvardi Therapeutics reports return on equity of -87.0% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 15.62M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. The next earnings report is expected on 31 March 2027.